{"prompt": "['(i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and', 'emailing the form using the fax number or email address provided to investigators.', '5.4.2.2', 'Events That Occur after Study Drug Initiation', 'After initiation of emicizumab study drug, serious adverse events and adverse events of', 'special interest will be reported until the last scheduled study visit (see Section 5.3.1).', 'Investigators should record all case details that can be gathered immediately (i.e., within 24', 'hours after learning of the event) on the Adverse Event eCRF and submit the report via the', 'electronic data capture (EDC) system. A report will be generated and sent to Roche Safety', 'Risk Management by the EDC system.', '5.4.3.1', 'Pregnancies in Female Patients', 'Female patients of childbearing potential will be instructed to immediately inform the', 'investigator if they become pregnant during the study or within 24 weeks after the last dose', 'of emicizumab study drug. A Clinical Trial Pregnancy Reporting Form should be completed', 'and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours after', 'learning of the pregnancy), either by faxing or by scanning and emailing the form using the', 'fax number or email address provided to investigators. Pregnancy should not be recorded on', 'the', 'Adverse Event eCRF. The investigator should discontinue emicizumab study drug-and', 'counsel the patient, discussing the risks of the pregnancy and the possible effects on the', 'fetus. Monitoring of the patient should continue until conclusion of the pregnancy. Any', 'serious adverse events associated with the pregnancy (e.g., an event in the fetus, an event', 'in the mother during or after the pregnancy, or a congenital anomaly/birth defect in the child)', 'should be reported on the Adverse Event eCRF. In addition, the investigator will submit a', 'Clinical Trial Pregnancy Reporting Form when updated information on the course and', 'outcome of the pregnancy becomes available.', '5.4.3.4', 'Congenital Anomalies/Birth Defects', 'Any congenital anomaly/birth defect in a child born to a female patient exposed to', 'emicizumab study drug-should be classified as a serious adverse event, recorded on the', 'Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours', 'after learning of the event; see Section 5.4.2).', '6.', 'STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN', 'The primary analysis population is all patients who have received at least one dose of', 'emicizumab study medication (safety population). The intent-to-treat (ITT) population includes', 'all enrolled patients.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '42 / Protocol MO39129, Version 3']['6.2', 'SUMMARIES OF CONDUCT OF STUDY', 'Flow of patients through the study will be displayed in a \"Consolidated Standards of', \"Reporting Trials (CONSORT)' diagram. A clear account of all patients who enrolled in the\", 'study and who entered, discontinued, and completed the initial and maintenance phases of', 'the study will be displayed. The reasons for premature discontinuation from study treatment', 'and the reasons for study withdrawal will be described. In addition, the number of patients', 'who received dose up-titration will also be described. Enrollment and major protocol', 'deviations will be listed and evaluated for their potential effects on the interpretation of study', 'results. The type of-Major protocol violations-deviation and the number of patients with at', 'least one violation-major protocol deviation will be summarized in terms of both the safety and', 'ITT populations.', '6.3', 'SUMMARIES OF DEMOGRAPHIC AND BASELINE CHARACTERISTICS', 'Demographic and baseline characteristics (including age, sex, and self-reported race and', 'ethnicity) will be summarized using means, standard deviations, medians, and ranges for', 'continuous variables and proportions-frequencies and percentages for categorical variables, as', 'appropriate. For each variable (continuous or categorical), the number of available', 'observations will be reported. Medical history will be tabulated and previous concomitant', 'medications will be summarized.', '6.4', 'SAFETY ANALYSES', 'The primary objective of this study is to evaluate the overall safety and tolerability of', 'prophylactic administration of emicizumab in patients with congenital hemophilia A who have', 'persistent inhibitors against FVIII at enrollment. Of primary interest in this study are the', 'incidence and severity of all adverse events, including thromboembolic events,', 'microangiopathic hemolytic anemia or TMA, systemic hypersensitivity, anaphylaxis, and', 'anaphylactoid events.', 'All adverse events will be assessed according to the WHO toxicity grading scale. The', 'incidence, type, and grade of adverse events will be summarized according to the primary', 'system-organ class (SOC) and, within each SOC, by Medical Dictionary for Regulatory', 'Activities (MedDRA) preferred term. For each adverse event, data will be provided on the', 'timing (start and stop date, time of onset in comparison with last dose of emicizumab', 'received, and doses of emicizumab received), severity, relationship to emicizumab study drug,', 'outcome, and effect on therapy. The data may be presented together with two-sided 95%', 'Clopper-Pearson Cls if appropriate.', 'In addition, as part of the safety evaluation, additional assessments will be summarized', 'descriptively as follows:', 'Laboratory parameters (hematology and chemistry):', 'These parameters will be presented in shift tables of WHO toxicity grade at baseline', 'versus worst grade during the treatment period. Selected laboratory parameters will', 'Emicizumab - F. Hoffmann-La Roche Ltd', '43 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}